Analysis Tools|
Allele Symbol Allele Name Allele ID |
Afg3l1tm1.1Arte targeted mutation 1.1, TaconicArtemis MGI:5817724 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice are viable, fertile and overtly normal up to 78 weeks of age and show no detectable myelination defects or axonal degeneration in the brain and the spinal cord up to 1 year of age
• no mitochondrial abnormalities are observed in spinal cord
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 10 weeks of age, tamoxifen-treated mice show a strong reduction of mt-YFP+ melanoblasts in the outer root sheath of the hair follicle
• at 28 weeks of age, pigmented hair follicles and c-KIT+ melanoblasts are significantly reduced in dorsal skin, suggesting that premature hair greying is caused by progressive loss of melanoblasts that share a common developmental origin with Schwann cells
|
|
• tamoxifen-treated mice show progressive and rapid loss of targeted (mt-YFP+) oligodendrocytes in the corpus callosum after 6 weeks of age, with only a few targeted cells remaining at 28 weeks
• at 10 weeks, the number of total APC+ cells is significantly decreased both in the corpus callosum and in the spinal cord
• at 10 weeks, the % of mt-YFP+ cells in the corpus callosum that are also APC+ is significantly reduced, while the % of APC- Olig2- targeted cells is significantly increased
• surprisingly, the number of mature oligodendrocytes and the size of APC+ cells is increased at 28 weeks of age; enlarged APC+ cells do not co-localize with mt-YFP+ cells but are in fact intensively positive for Olig2 staining
|
|
• at 10 weeks of age, non-myelinating Schwann cells in the subcutaneous nerve plexus show a significant decrease of mt-YFP signal
• at 10 weeks of age, tamoxifen-treated mice show clear signs of Schwann cell pathology affecting preferentially small calibre unmyelinated fibers; several Remak bundles appear affected with individual unmyelinated axons touching each other and showing initial signs of axonal degeneration; inner tongue swellings are also observed in myelinated axons
|
|
• at 10 weeks of age, tamoxifen-treated mice show a reduction of mt-YFP signal within the sciatic nerve
|
|
• tamoxifen-treated mice show death of mature oligodendrocytes followed by compensatory repopulation by untargeted oligodendrocytes
• at 8 weeks of age, several oligodendrocytes undergo dark cell death, a caspase-independent form of death characterized by strong cytoplasmic condensation, chromatin clumping, ruffling of the cell membrane, but no blebbing of the nucleus or plasma membrane
• only a few TUNEL+ apoptotic cells are noted in the corpus callosum at 7 weeks of age
|
|
• at 28 weeks of age, non-myelinated large caliber axons and multivesicular disintegration of adaxonal myelin lamellae are observed in the sciatic nerve
|
|
• at 6 weeks of age, oligodendrocytes of tamoxifen-treated mice exhibit swollen mitochondria
|
|
• at 8 but not at 6 weeks of age, oligodendrocytes of tamoxifen-treated mice exhibit loss of COX1 staining, indicating impaired mitochondrial function
• cytochrome c is undetectable in several swollen mitochondria in oligodendrocytes at 8 weeks of age
|
|
• at 10 weeks of age, tamoxifen-treated mice show a strong reduction of mt-YFP+ melanoblasts in the outer root sheath of the hair follicle
• at 28 weeks of age, pigmented hair follicles and c-KIT+ melanoblasts are significantly reduced in dorsal skin, suggesting that premature hair greying is caused by progressive loss of melanoblasts that share a common developmental origin with Schwann cells
|
|
• at 28 weeks of age, tamoxifen-treated mice show reduced fat deposited in the dermis
• however, general skin structure is normal
|
|
• at 28 weeks of age, c-KIT+ melanocytes are significantly reduced in dorsal skin
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 13 and 28 weeks of age, tamoxifen-treated mice exhibit significantly decreased fat mass relative to single Afg3l1tm1.1Arte homozygous (control) mice
|
|
• starting at 8 weeks of age, tamoxifen-treated mice show decreased body weight relative to control mice
• difference in body weight persists even after adding food pellets directly in the cage
|
|
• at 11-13 weeks of age, tamoxifen-treated mice spend less time on the rotating rod than control mice
• during a beam walking test, the number of foot slips is significantly higher at 13 weeks and dramatically increased at 28 weeks of age relative to that in control mice
|
|
• demyelination is associated with microglia activation
• tamoxifen-treated mice exhibit activated microglia in the corpus callosum at 28 weeks of age
|
|
• tamoxifen-treated mice show marked loss of white matter in the corpus callosum, internal capsule, and cerebellum at 28 weeks of age
|
|
• demyelination is associated with astrocyte activation, as shown by upregulation of GFAP in spinal cord and brain lysates at 10 and 28 weeks of age
|
|
• tamoxifen-treated mice show progressive demyelination in the spinal cord white matter, with some axons showing adaxonal myelin detachment at 13 weeks and marked signs of demyelination at 18 weeks of age
• the g ratio, expressing the ratio between the diameter of the inner axon and the total fiber diameter, is significantly increased at 28 weeks of age
|
|
• tamoxifen-treated mice show signs of secondary axonal degeneration in the spinal cord, with accumulation of organelles and material in axons at 28 weeks of age
|
|
• tamoxifen-treated mice show progressive demyelination in the lumbar spinal cord, resulting in demyelinated and degenerating axons as well as dark cells in the antero-lateral funiculus at 28 weeks of age
• Gallyas' silver staining of brain myelinated tracts showed prominent loss of white matter in the corpus callosum, internal capsule, and cerebellum at 28 weeks of age
• progressive loss of myelin is confirmed by western blot analysis of myelin proteins in spinal cord and brain lysates at 10 and 28 weeks of age
|
|
• tamoxifen-treated mice show premature and progressive hair greying starting ventrally close to the forelimbs at 10 weeks, resulting in a grey belly at 17 weeks, and finally extending to the dorsal skin at 28 weeks of age; no such phenotype is observed in control mice
|
|
• at 13 and 28 weeks of age, tamoxifen-treated mice exhibit significantly decreased fat mass relative to single Afg3l1tm1.1Arte homozygous (control) mice
|
|
• demyelination is associated with microglia activation
• tamoxifen-treated mice exhibit activated microglia in the corpus callosum at 28 weeks of age
|
|
• demyelination is associated with microglia activation
• tamoxifen-treated mice exhibit activated microglia in the corpus callosum at 28 weeks of age
|
|
• tamoxifen-treated mice show premature and progressive hair greying starting ventrally close to the forelimbs at 10 weeks, resulting in a grey belly at 17 weeks, and finally extending to the dorsal skin at 28 weeks of age; no such phenotype is observed in control mice
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
